As chimeric antigen receptor (CAR) T cells have displayed an unprecedented efficacy in the treatment of CD19-positive malignances, it is believed that this cell therapy will be a milestone in the history of mankind's conquering of cancer. However, there are some issues that restrict CAR T cells from reaching their optimal anti-tumor capacity, especially in the treatment of solid tumors. Inhibitory cytokines, immune checkpoint molecules, hypoxia and other adverse factors have been reported to be involved in this process. To obtain better efficacy in the treatment of leukemia and solid tumors, we need to continuously upgrade CAR T cell technology by incorporating novel functional elements into CAR T cells to overcome these restrictions. In this review, we summarize recent advances regarding this topic.
Background
Benefiting from the remarkable therapeutic outcome of chimeric antigen receptor (CAR) T cell treatment of refractory/relapsed B cell malignancy, CAR T cells are transitioning from the lab to the cancer ward. Several CAR-T products are in the advanced stage of clinical development [1] [2] [3] . CARs are recombinant receptors that generally consist of scFv, hinge, transmembrane domain, costimulatory molecule and CD3 ζ chain. Current research on CAR T cells mainly focuses on exploring new scFvs that are expressed at high levels on tumor cell surfaces rather than in healthy tissue and investigating an appropriate co-stimulatory intensity that enhances CAR T cell killing capacity and persistence [4] [5] [6] . However, there are some issues that restrict CAR T cells from reaching an optimal anti-tumor capacity, especially in the treatment of solid tumors [7] . Such as inhibitory cytokines, immune checkpoint molecules, hypoxia and other adverse factors hindering CAR T cell from efficiently expanding and killing tumor cells. Some researchers are attempting to combine some novel elements into CAR vectors to make CAR T cell slip the leash of aforementioned restrictions and thereby exhibiting optimal antitumor capacity ( Fig. 1) . In this review, we summarize the progresses of the incorporation of novel functional elements to improve CAR T cells, which have obtained prominent results.
Cytokines
IL-12 is a heterodimeric inflammatory cytokine produced by activated antigen-presenting cells (APCs), neutrophils, and macrophages. Scientific research has shown that a hostile tumor microenvironment can be significantly regulated by IL-12 through multiple mechanisms, including reactivation of anergic tumor-infiltrated lymphocytes (TILs), inhibition of Treg-mediated suppression of effector T cells, recruitment of NK cells to the tumor site, and inhibition of IL-10 and transforming growth factor-β (TGF-β) secretion by tumor-associated macrophages (TAM). In a novel syngeneic tumor model, Pegram et al. [8] demonstrated that tumor elimination requires both CD4+ and CD8+ T cell subsets, autocrine IL-12 stimulation, and subsequent IFN-γ secretion by CAR T cells. Therefore, they modified CD19-targeted CAR T cells to constitutively secrete IL-12, and the results showed that this treatment was able to safely eradicate established
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Experimental Hematology & Oncology To protect CAR-PSCA T cells from the inhibitory effects of IL4, Somala Mohammed transgenically expressed a custom inverted cytokine receptor (ICR) in which the IL-4 receptor ectodomain was fused to the IL-7 receptor endodomain, switching the inhibitory effects to promoting effects to ultimately result in potent and sustained anti-tumor effects [10] . To achieve the selective expansion of CAR T cells, Whilding et al. [11] co-expressed an IL-4-responsive fusion gene (4αβ), which fused the IL-4 receptor α ectodomain to the shared human IL-2/IL-15 receptor β transmembrane and endodomain regions. Binding of IL-4 led to the delivery of a potent and selective growth signal in 4αβ+ CAR T cells.
Immune checkpoint molecules
As an evasion mechanism, many tumors are able to express various immune checkpoint molecules, resulting in the exhaustion of T cells that cannot prevent tumor progression. Emerging clinical data have highlighted the importance of the PD-L1/PD-1 immune inhibitory axis, and immune checkpoint blockers targeting both PD1 and PD-L1 have obtained great success in cancer therapy [12, 13] . Suarez et al. [14] 
Hypoxia
Hypoxia is a hallmark of a hostile tumor microenvironment, and tumor cells have high levels of oxidative stress and reactive oxygen species (ROS) production that substantially impair the antitumor activity of adoptively transferred T cells. Ligtenberg et al. [19] presented a strategy to render antitumor T cells more resilient toward ROS by co-expressing catalase along with a tumor-specific CAR to increase their anti-oxidative capacity by metabolizing H 2 O 2 . CAR T cells engineered to co-express catalase (CAR-CAT) showed increased levels of intracellular catalase and sharp decreases in ROS accumulation while maintaining their antitumor activity despite high H 2 O 2 levels. More importantly, CAR T cells co-expressing catalase substantially protected bystander effector cells from oxidative stress-mediated repression. The lung is an oxygen-rich environment that frequently permits colonization by metastatic tumor cells. The prolyl hydroxylase domain (PHD) functions as an 
Chemotherapeutic drugs and kinase inhibitors
Chemotherapeutic drugs and kinase inhibitors play important roles in clinical cancer treatment. In order to elicit stronger antitumor activity, some researchers are attempting to combine CAR T cell therapy with these drugs. Fraietta et al. [22] found that T cells from chronic lymphocytic leukemia (CLL) patients usually exhibit deficiencies in proliferation, and this proliferative defect is completely reversed after long-term ibrutinib therapy. Ibrutinib is a first-in-class irreversible inhibitor of Bruton tyrosine kinase (BTK), which can irreversibly inhibit the IL-2 inducible T cell kinase (ITK). Ibrutinib inhibits Th2-polarized CD4 T cells, thus skewing T cells toward a Th1 anti-tumor immune response. Therefore, Fraietta et al. combined ibrutinib with CTL019 for treatment of CLL, and the results demonstrated that Ibrutinib increased the expansion of CTL019 and decreased PD-1 and CD200 expression from CLL patients ex vivo. Moreover, they found that continuous ibrutinib treatment could enhance CTL019 efficacy in drug-resistant ALL and CLL mouse models. Ruella et al. [23] also added Ibrutinib to CTL019 for the treatment of mantle cell lymphoma; the results demonstrated that 80-100% of mice in the CTL019+ ibrutinib arm and 0-20% of mice in the CTL019 arm remained in long-term remission (p < 0.05 
Conclusion
In the above studies, in order to achieve better anti-tumor efficacy in the CAR T cell therapy, CAR T cells were modified to contain another single functional elements.
The results demonstrate that incorporation of functional elements can significantly enhance the anti-tumor efficacy of CAR T cells. However, CAR T cells will encounter a more complicated and wicked tumor microenvironment after infuse into patients. Therefore, in order to make CAR T cells display the best anti-tumor capacity in clinic, it is better to simultaneously incorporate multiple functional elements into CAR T cells. For example, CAR T cells co-express PD1:CD28 chimera and IL12 can break the restriction imposed by immune inhibitory molecules and by the lack of cytokine signals. Expand CAR T cells with DMOG in vitro is also an option to make CAR T cells better overcome the hypoxic tumor microenvironment. By combining these approaches, CAR T cells can resist several adverse factors and finally we obtain more powerful CAR T cells. 
